The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway

作者：Xueying Li, Zhaoqing Han, Wang Feng, Jianou Qiao · 发表于：Allergy Asthma and Clinical Immunology · 年份：2022 · DOI：10.1186/s13223-022-00652-8 · 被引用次数：17 · 研究领域：Dermatology and Skin Diseases、Asthma and respiratory diseases、Psoriasis: Treatment and Pathogenesis

BACKGROUND: Epidemiological studies have revealed a link between atopic dermatitis (AD) and asthma. AS1517499, a selective signal transducer and activation of transcription 6 (STAT6) inhibitor, has been shown to effectively block this connection. In this study, we further explored the underlying mechanism by constructing an AD mouse model. METHODS: Female BALB/c mice were randomly divided into four groups (n = 10/group). The AD mouse model was established by 2,4-dinitrochlorobenzene induction with repeated ovalbumin challenge. AS1517499 and corn oil were used as treatment interventions. The features of airway inflammation, remodeling, and hyperactivity were analyzed. RESULTS: Active use of AS1517499 in AD mice effectively reduced Th2-related cytokine levels, alleviated airway eosinophil and lymphocyte infiltration, and regulated GATA3/Foxp3 levels and subepithelial collagen deposition. These changes might be due to specific blockade of the STAT6 signaling pathway. CONCLUSION: AS1517499 could partially block the association between AD and asthma by specifically inhibiting the STAT6 signaling pathway.